On Thursday, First Solar, Inc. (NASDAQ:FSLR)’s shares declined -0.76% to $50.97.
First Solar, Inc. (FSLR) declared that it has signed an agreement to supply its high performance photovoltaic (PV) modules to power the 200 megawatt (MW)AC second phase of the Mohammed bin Rashid Al Maktoum Solar Park in Dubai, the United Arab Emirates.
First Solar, Inc. provides solar energy solutions worldwide. The company operates through two segments, Components and Systems. The Components segment designs, manufactures, and sells solar modules that convert sunlight into electricity. This segment manufactures cadmium telluride and crystalline silicon modules for project developers and system integrators, in addition to owners and operators of photovoltaic (PV) solar power systems.
8Point3 Energy Partners LP (NASDAQ:CAFD)’s shares dropped -1.53% to $20.00.
8Point3 Energy Partners LP (CAFD) a limited partnership formed by First Solar, Inc. and SunPower Corporation to own and operate a portfolio of selected solar energy generation assets, declared recently that it has priced an initial public offering (the “IPO”) of 20,000,000 Class A shares, representing limited partner interests in 8point3 Energy Partners (the “shares”), at a price of $21.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 3,000,000 shares from 8point3 Energy Partners at the IPO price, less the underwriting discount. The shares of 8point3 Energy Partners will be listed on the NASDAQ Global Select Market under the symbol “CAFD” and start trading on June 19, 2015.
8point3 Energy Partners intends to use all of the net proceeds of the IPO to purchase the common units of 8point3 Operating Company, LLC (“8point3 Operating Company”), the entity that holds 8point3 Energy Partners’ project assets. 8point3 Operating Company intends to use the proceeds from the sale of its common units (i) to make a cash distribution to each of First Solar and SunPower and (ii) for general corporate purposes, counting to fund future acquisition opportunities.
Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as lead book running managers for the IPO. Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Credit Agricole Securities (USA) Inc. are acting as joint book-running managers for the IPO.
8point3 Energy Partners LP, together with its auxiliaries, owns, operates, and acquires solar energy generation projects. It would have interests in 432 MW of solar energy projects, which serve utility, commercial and industrial, and residential customers in the United States and other select markets.
At the end of Thursday’s trade, Monster Beverage Corp (NASDAQ:MNST)‘s shares surged 2.87% to $136.77.
The Coca-Cola Company (KO) and Monster Beverage Corporation (MNST) announced today the closing of the previously announced strategic partnership related to an equity investment, business transfers and expanded distribution in the global energy drink category. As a result of the transaction, The Coca-Cola Company now owns an approximate 16.7% stake in Monster.
Monster Beverage Corporation, through its auxiliaries, develops, markets, sells, and distributes alternative beverage category beverages in the United States and internationally. It operates in two segments, Direct Store Delivery and Warehouse. The Direct Store Delivery segment offers carbonated energy drinks, non-carbonated dairy based coffee plus energy drinks, non-carbonated energy shakes containing proteins, carbonated energy drinks containing nitrous oxide, non-carbonated energy drinks with electrolytes, and ready-to-drink iced teas.
Galena Biopharma Inc (NASDAQ:GALE), ended its Thursday’s trading session with -2.14% loss, and closed at $1.83.
Galena Biopharma Inc (GALE) a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, recently declared that data from the Company’s Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association 20th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia (ET) and other myeloproliferative neoplasms (MPNs).
The poster presentation, entitled, “Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis,” was presented on Saturday, June 13, 2015. The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled. The efficacy shown in the trial compares favorably to historical anagrelide immediate release (IR) response rates with the following platelet response: overall response rate (ORR) of 78% (14/18); complete response (CR) of 39% (7/18); partial response (PR) of 39% (7/18). The median time to response was 5 weeks (range, 3-10), and the median duration of response has not yet been reached. Based on the data, the investigators concluded that GALE-401 remains a viable potential treatment option for MPNs, and a randomized trial comparing GALE-401 as compared to anagrelide IR is warranted. Final data from the GALE-401 Phase 2 trial is predictable to be presented at the American Society of Hematology conference in December.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
